Applied aspects of SLCO1B1 pharmacogenetic testing for predicting of statin-induced myopathy and personalization of statins therapy

被引：1

作者：

Sychev, D. A. ^{[1
]}

Shuev, G. N. ^{[2
]}

Prokofiev, A. B. ^{[3
]}

机构：

[1] Russian Med Acad Postgraduate Educ, Barricadnaya ul 2-1, Moscow R-123995, Russia

[2] M Sechenov First Moscow State Med Univ, Trubetskaya ul 8-2, Moscow R-119991, Russia

[3] Ctr Clin Pharmacol Res Ctr Evaluat Med Produc, Petrovsky boul 8, Moscow R-127051, Russia

来源：

RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2013年 / 9卷 / 06期

关键词：

pharmacogenetics; statins; myopathy; SLCO1B1; personalized medicine;

D O I：

10.20996/1819-6446-2013-9-6-698-700

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical significance of the SLCO1B1 gene polymorphism (encoding an organic anion transport polipeptide) in the development of statin induced myopathy is considered. Possible tactics of statin dose determination on the basis of pharmacogenetic testing is discussed. Indications for the use of this approach in clinical practice that should increase the efficacy and safety of the statin therapy are also considered.

引用

页码：698 / 700

页数：3

共 10 条

[1]

Becquement L, 2011, PHARMACOGENOMICS, V12, P113, DOI [10.2217/pgs.10.147, 10.2217/PGS.10.147]

[2] Individualising the risks of statins in men and women in England and Wales: population-based cohort study [J].

Hippisley-Cox, Julia ;

Coupland, Carol .

HEART, 2010, 96 (12) :939-947

[3]

Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936

[4] Cardiovascular Pharmacogenomics: Current Status and Future Directions-Report of a National Heart, Lung, and Blood Institute Working Group [J].

Musunuru, Kiran ;

Roden, Dan M. ;

Boineau, Robin ;

Bristow, Michael R. ;

McCaffrey, Timothy A. ;

Newton-Cheh, Christopher ;

Paltoo, Dina N. ;

Rosenberg, Yves ;

Wohlgemuth, Jay G. ;

Zineh, Issam ;

Hasan, Ahmed A. K. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (02)

[5]

Perez-Castrillon JL, 2010, INT J ENDOCRINOL, V2010, P3207

[6] Integrated assessment of statin-associated muscle damage predictors in patients with ischemic heart disease [J].

Petrov, V. I. ;

Smuseva, O. N. ;

Solovkina, Yu. V. .

RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2013, 9 (03) :247-250

[7] Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D [J].

Riphagen, Ineke J. ;

van der Veer, Eveline ;

Muskiet, Frits A. J. ;

DeJongste, Mike J. L. .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (07) :1247-1252

[8]

Sirotkina AM, 2013, 24 INT EXTR SCI PRAC, P90

[9]

Thompson Paul D, 2010, Prev Cardiol, V13, P104, DOI 10.1111/j.1751-7141.2009.00063.x

[10]

Voskoboynikov AM, 2013, B MED INTERNET C, V3, P975

← 1 →